Lung Cancer

News alerts, weekly reports and conference planners

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days (New B) osimertinib Sensitive : A1 J Clin Oncol - 2d	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days osimertinib Sensitive : A1 J Clin Oncol - 2 days - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days (New B) osimertinib Sensitive : A1 J Clin Oncol - 2d	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days osimertinib Sensitive : A1 J Clin Oncol - 2 days - (New B)
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TPX-0005 Sensitive: B - Late Trials IASLC-TTLC 2023 - 5 days (New C3) TPX-0005 Sensitive : B IASLC-TTLC 2023 - 5d	TPX-0005 Sensitive: B - Late Trials IASLC-TTLC 2023 - 5 days TPX-0005 Sensitive : B IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C2 – Inclusion Criteria IASLC-TTLC 2023 - 5 days (New C3) BI 1810631 Sensitive : C2 IASLC-TTLC 2023 - 5d	BI 1810631 Sensitive: C2 – Inclusion Criteria IASLC-TTLC 2023 - 5 days BI 1810631 Sensitive : C2 IASLC-TTLC 2023 - 5 days - (New C3)
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	TPX-0005 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) TPX-0005 Sensitive : C3 IASLC-TTLC 2023 - 5d	TPX-0005 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days TPX-0005 Sensitive : C3 IASLC-TTLC 2023 - 5 days - (New C3)
Chr del(9p) + PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	Chr del(9p) + PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5d	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + PTEN mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + PTEN mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + BRCA1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + BRCA1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + ARID1A mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + ARID1A mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + NF1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + NF1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + RB1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + RB1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
KEAP1 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5d	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
STK11 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5d	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR G719A	Non Small Cell Lung Cancer	EGFR G719A	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) amivantamab-vmjw Sensitive : C4 IASLC-TTLC 2023 - 5d	amivantamab-vmjw Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days amivantamab-vmjw Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
MET F1200I	Lung Adenocarcinoma	MET F1200I	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5d	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
MET H1094Y	Lung Adenocarcinoma	MET H1094Y	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5d	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression	Lung Cancer	SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression	Lung Cancer	pembrolizumab Resistant: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) pembrolizumab Resistant : C4 IASLC-TTLC 2023 - 5d	pembrolizumab Resistant: C4 – Case Studies IASLC-TTLC 2023 - 5 days pembrolizumab Resistant : C4 IASLC-TTLC 2023 - 5 days - (New C4)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval FDA - 1 week (New A1) pembrolizumab Sensitive : A1 FDA - 1wk	pembrolizumab Sensitive: A1 - Approval FDA - 1 week pembrolizumab Sensitive : A1 FDA - 1 week - (New A1)
ALK fusion	Lung Adenocarcinoma	ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C2 – Inclusion Criteria Anticancer Drugs - 1 week (New C4) alectinib Sensitive : C2 Anticancer Drugs - 1wk	alectinib Sensitive: C2 – Inclusion Criteria Anticancer Drugs - 1 week alectinib Sensitive : C2 Anticancer Drugs - 1 week - (New C4)
ROS1 fusion + KRAS G12C	Non Small Cell Lung Cancer	ROS1 fusion + KRAS G12C	Non Small Cell Lung Cancer	entrectinib Resistant: C4 – Case Studies NPJ Precis Oncol - 1 week (New C4) entrectinib Resistant : C4 NPJ Precis Oncol - 1wk	entrectinib Resistant: C4 – Case Studies NPJ Precis Oncol - 1 week entrectinib Resistant : C4 NPJ Precis Oncol - 1 week - (New C4)
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week (New C4) alectinib Sensitive : C4 Anticancer Drugs - 1wk	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week alectinib Sensitive : C4 Anticancer Drugs - 1 week - (New C4)
TMB-H + PD-L1 expression	Lung Cancer	TMB-H + PD-L1 expression	Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies Medicine (Baltimore) - 1 week (New C4) pembrolizumab Sensitive : C4 Medicine (Baltimore) - 1wk	pembrolizumab Sensitive: C4 – Case Studies Medicine (Baltimore) - 1 week pembrolizumab Sensitive : C4 Medicine (Baltimore) - 1 week - (New C4)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks (New C3) crizotinib Sensitive : A1 Cancer Manag Res - 2wk	crizotinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks crizotinib Sensitive : A1 Cancer Manag Res - 2 weeks - (New C3)
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks (New A1) serplulimab Sensitive : A1 Henlius Press Release - 2wk	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks serplulimab Sensitive : A1 Henlius Press Release - 2 weeks - (New A1)
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks (New A1) penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2wk	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2 weeks - (New A1)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks (New B) toripalimab Sensitive : B BioSpace - 2wk	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks toripalimab Sensitive : B BioSpace - 2 weeks - (New B)
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval Future Oncol - 2 weeks (New B) osimertinib Sensitive : A1 Future Oncol - 2wk	osimertinib Sensitive: A1 - Approval Future Oncol - 2 weeks osimertinib Sensitive : A1 Future Oncol - 2 weeks - (New B)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks (New C3) alectinib Sensitive : A1 Cancer Manag Res - 2wk	alectinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks alectinib Sensitive : A1 Cancer Manag Res - 2 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval Adv Ther - 2 weeks (New C3) amivantamab-vmjw Sensitive : A1 Adv Ther - 2wk	amivantamab-vmjw Sensitive: A1 - Approval Adv Ther - 2 weeks amivantamab-vmjw Sensitive : A1 Adv Ther - 2 weeks - (New C3)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks (New C3) ceritinib Sensitive : A1 Cancer Manag Res - 2wk	ceritinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks ceritinib Sensitive : A1 Cancer Manag Res - 2 weeks - (New C3)
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label Cancer Lett - 2 weeks (New D) osimertinib Sensitive : C1 Cancer Lett - 2wk	osimertinib Sensitive: C1 - Off-label Cancer Lett - 2 weeks osimertinib Sensitive : C1 Cancer Lett - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks (New C4) osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2wk	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2 weeks - (New C4)
EGFR L860R	Lung Adenocarcinoma	EGFR L860R	Lung Adenocarcinoma	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks (New D) osimertinib Sensitive : D Cancer Lett - 2wk	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks osimertinib Sensitive : D Cancer Lett - 2 weeks - (New D)
MYCL expression	Non Small Cell Lung Cancer	MYCL expression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks (New B) MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3wk	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3 weeks - (New B)
MYCN expression	Non Small Cell Lung Cancer	MYCN expression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks (New B) MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3wk	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3 weeks - (New B)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks (New A1) mobocertinib Sensitive : A1 Takeda Press Release - 3wk	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks mobocertinib Sensitive : A1 Takeda Press Release - 3 weeks - (New A1)
PBRM1 mutation	Non Small Cell Lung Cancer	PBRM1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Front Genet - 3 weeks (New C3) Immunotherapy Resistant : C3 Front Genet - 3wk	Immunotherapy Resistant: C3 – Early Trials Front Genet - 3 weeks Immunotherapy Resistant : C3 Front Genet - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BPI-7711 Sensitive: C3 – Early Trials BMC Med - 3 weeks (New C3) BPI-7711 Sensitive : C3 BMC Med - 3wk	BPI-7711 Sensitive: C3 – Early Trials BMC Med - 3 weeks BPI-7711 Sensitive : C3 BMC Med - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + AB-329 Sensitive: C3 – Early Trials Cancer Med - 3 weeks (New C3) gefitinib + AB-329 Sensitive : C3 Cancer Med - 3wk	gefitinib + AB-329 Sensitive: C3 – Early Trials Cancer Med - 3 weeks gefitinib + AB-329 Sensitive : C3 Cancer Med - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks (New C3) osimertinib + MEDI9447 Sensitive : C3 J Thorac Oncol - 3wk	osimertinib + MEDI9447 Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks osimertinib + MEDI9447 Sensitive : C3 J Thorac Oncol - 3 weeks - (New C3)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression	Non Small Cell Lung Cancer	KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression	Non Small Cell Lung Cancer	anlotinib + camrelizumab Sensitive: C4 – Case Studies Front Pharmacol - 3 weeks (New C4) anlotinib + camrelizumab Sensitive : C4 Front Pharmacol - 3wk	anlotinib + camrelizumab Sensitive: C4 – Case Studies Front Pharmacol - 3 weeks anlotinib + camrelizumab Sensitive : C4 Front Pharmacol - 3 weeks - (New C4)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1

Lung Cancer

Associations(3460)

Associations
(3460)